SAGIMET BIOSCIENCES INC-A
SGMT · NASDAQ
Updated at 2026-10-14 08:52:42
- Today's High
- $8.74
- Today’s Low
- $7.88
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $8.85
- Previous Close
- $8.80
- Volume
- 1.15M
- Market Cap
- $619M
- P/E Ratio
- --
- EPS
- $-1.28
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 155 BOVET ROAD, SAN MATEO, CA, UNITED STATES, 94402
- Country
- US
- Listing Date
- 2023-07-14
- Fiscal Year End
- December
- Shares Outstanding
- 61.75M
- CIK
- 0001400118
- Website
- sagimet.com
Sagimet Biosciences Inc. (SGMT) is an innovative biotechnology company focused on developing breakthrough treatments for metabolic diseases, particularly non-alcoholic steatohepatitis (NASH). The company is actively advancing its lead therapeutic candidate through various clinical trial phases, employing cutting-edge mechanisms designed to enhance patient outcomes. Backed by a robust management team and a strong intellectual property portfolio, Sagimet is strategically positioned to capitalize on the growing market demand for effective metabolic disease therapies, making it an attractive investment proposition for institutional investors in the dynamic biotech sector.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
Operating Expenses
2026-06-30
$15.81M
2026-03-31
$11.71M
2025-12-31
$10.76M
2025-09-30
$14.33M
Net Income
2026-06-30
-$13.95M
2026-03-31
-$10.65M
2025-12-31
-$9.56M
2025-09-30
-$12.9M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
Earnings Per Share
2026-06-30
$-0.26
2026-03-31
$-0.33
2025-12-31
$-0.29
2025-09-30
$-0.40
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$13.95M
2026-03-31
-$10.65M
2025-12-31
-$12.19M
2025-09-30
-$12.9M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | $15.81M | $11.71M | $10.76M | $14.33M |
| Net Income | -$13.95M | -$10.65M | -$9.56M | -$12.9M |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $-0.26 | $-0.33 | $-0.29 | $-0.40 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$13.95M | -$10.65M | -$12.19M | -$12.9M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.